Literature DB >> 20146264

MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Chiara Braconi1, Nianyuan Huang, Tushar Patel.   

Abstract

UNLABELLED: Although the inflammation-associated cytokine interleukin-6 (IL-6) has been implicated in cholangiocarcinoma growth, the relationship between IL-6 and oncogenic changes is unknown. IL-6 can increase expression of DNA methyltransferase-1 (DNMT-1) and epigenetically regulate the expression of several genes, including microRNAs (miRNAs). DNMT-1 up-regulation occurs in hepatobiliary cancers and is associated with a poor prognosis. To understand the potential regulation of DNMT-1 by IL-6-dependent miRNAs, we examined the expression of a group of miRNAs which have sequence complementarity to the 3'-untranslated region of DNMT-1, namely miR-148a, miR-152, and miR-301. The expression of these miRNAs was decreased in cholangiocarcinoma cells. Moreover, the expression of all three miRNAs was decreased in IL-6-overexpressing malignant cholangiocytes in vitro and in tumor cell xenografts. There was a concomitant decrease in expression of the methylation-sensitive tumor suppressor genes Rassf1a and p16INK4a. Using luciferase reporter constructs, DNMT-1 was verified as a target for miR-148a and miR-152. Precursors to miR-148a and miR-152 decreased DNMT-1 protein expression, increased Rassf1a and p16INK4a expression, and reduced cell proliferation.
CONCLUSION: These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146264      PMCID: PMC3902044          DOI: 10.1002/hep.23381

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Cholangiocarcinoma.

Authors:  Tushar Patel
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-01

2.  Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.

Authors:  S Foja; M Goldberg; U Schagdarsurengin; R Dammann; A Tannapfel; W G Ballhausen
Journal:  Liver Int       Date:  2005-12       Impact factor: 5.828

3.  Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.

Authors:  J Park; L Tadlock; G J Gores; T Patel
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

4.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.

Authors:  Fanyin Meng; Roger Henson; Molly Lang; Hania Wehbe; Shail Maheshwari; Joshua T Mendell; Jinmai Jiang; Thomas D Schmittgen; Tushar Patel
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

5.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

Authors:  R Dammann; C Li; J H Yoon; P L Chin; S Bates; G P Pfeifer
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

Review 6.  The DNA methyltransferases of mammals.

Authors:  T H Bestor
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

7.  Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.

Authors:  Hania Wehbe; Roger Henson; Fanyin Meng; Janna Mize-Berge; Tushar Patel
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

8.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.

Authors:  Muller Fabbri; Ramiro Garzon; Amelia Cimmino; Zhongfa Liu; Nicola Zanesi; Elisa Callegari; Shujun Liu; Hansjuerg Alder; Stefan Costinean; Cecilia Fernandez-Cymering; Stefano Volinia; Gulnur Guler; Carl D Morrison; Kenneth K Chan; Guido Marcucci; George A Calin; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

9.  Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.

Authors:  Baek-Hee Kim; Nam-Yun Cho; Minhee Choi; Sun Lee; Ja June Jang; Gyeong Hoon Kang
Journal:  Arch Pathol Lab Med       Date:  2007-06       Impact factor: 5.534

10.  DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation.

Authors:  Bong-Kyeong Oh; Haeryoung Kim; Hye-Jung Park; Yhong-Hee Shim; Jinsub Choi; Chanil Park; Young Nyun Park
Journal:  Int J Mol Med       Date:  2007-07       Impact factor: 4.101

View more
  164 in total

1.  MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.

Authors:  Akao Zhu; Jiazeng Xia; Junbo Zuo; Shimao Jin; Hong Zhou; Lubin Yao; Hongyu Huang; Zhijun Han
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

Review 2.  MicroRNAs are shaping the hematopoietic landscape.

Authors:  Ute Bissels; Andreas Bosio; Wolfgang Wagner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination.

Authors:  Marcin P Mycko; Maria Cichalewska; Agnieszka Machlanska; Hanna Cwiklinska; Magdalena Mariasiewicz; Krzysztof W Selmaj
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-18       Impact factor: 11.205

4.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

5.  Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.

Authors:  Alexandru V Olaru; Yulan Cheng; Rachana Agarwal; Jian Yang; Stefan David; John M Abraham; Wayne Yu; John H Kwon; Mark Lazarev; Steven R Brant; Michael R Marohn; David F Hutcheon; Noam Harpaz; Stephen J Meltzer; Yuriko Mori
Journal:  Inflamm Bowel Dis       Date:  2011-08-09       Impact factor: 5.325

6.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

Review 7.  Aberrant DNA methylation in human cancers.

Authors:  Wen Li; Bi-Feng Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

Review 8.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

10.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.